Orthofix Medical (FRA:OM2) EBIT: €-34.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OM2 Orthofix Medical Inc FRA:OM2
60 GF Score
Price €8.70
GF Value €12.11
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Orthofix Medical EBIT?

Orthofix Medical FRA:OM2 +1.75% 60 EBIT is €-34.0 Mil as of Jun. 2026. GuruFocus rates FRA:OM2 with a GF Score™ of 60/100 and a GF Value™ of €12.11 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Orthofix Medical's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was €-7.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was €-34.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orthofix Medical's annualized ROC % for the quarter that ended in Jun. 2026 was -4.11%. Orthofix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -11.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orthofix Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -7.37%.


Orthofix Medical  (FRA:OM2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orthofix Medical's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-25.228 * ( 1 - 0% )/( (615.567 + 612.529)/ 2 )
=-25.228/614.048
=-4.11 %

where

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=757.781 - 55.145 - ( 90.107 - max(0, 136.285 - 387.243+90.107))
=612.529

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Orthofix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-30.944/( ( (127.067 + max(158.669, 0)) + (113.497 + max(160.96, 0)) )/ 2 )
=-30.944/( ( 285.736 + 274.457 )/ 2 )
=-30.944/280.0965
=-11.05 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(119.175 + 153.813 + 22.187) - (47.303 + 0 + 89.203)
=158.669

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.89 + 160.124 + 19.122) - (55.145 + 0 + 81.031)
=160.96

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orthofix Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=-33.993/461.357
=-7.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orthofix Medical EBIT Related Terms


Orthofix Medical EBIT Historical Data

* Premium members only.

The historical data trend for Orthofix Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthofix Medical EBIT Chart

Orthofix Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.32 -15.50 -128.42 -90.00 -62.62

Orthofix Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.91 -14.98 1.84 -13.12 -7.74

FRA:OM2 vs VMD, VREX, KIDS: EBIT Comparison

For the Medical Devices subindustry, Orthofix Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthofix Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's EV-to-EBIT falls into.


FRA:OM2
60GF Score
Orthofix Medical Inc FRA:OM2
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orthofix Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-34.0 Mil mean?
Orthofix Medical (FRA:OM2) has a EBIT of €-34.0 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Orthofix Medical.
Is Orthofix Medical's EBIT too high?
Orthofix Medical's current EBIT is €-34.0 Mil. Overall, Orthofix Medical has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's EBIT compare to VMD and VREX?
Orthofix Medical's EBIT of €-34.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Orthofix Medical. Orthofix Medical's current EBIT is €-34.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (FRA:OM2) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.11, compared to a current price of €8.70 — trading 28.2% below its estimated fair value. The current EBIT is €-34.0 Mil. Orthofix Medical's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Orthofix Medical (FRA:OM2), the current EBIT is €-34.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orthofix Medical (FRA:OM2) Overvalued in 2026?

Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued. The current stock price of €8.70 is trading 28.2% below its estimated GF Value™ of €12.11. GuruFocus considers Orthofix Medical to be Modestly Undervalued.

Key valuation signals for FRA:OM2:

  • EBIT: €-34.0 Mil
  • GF Value™: €12.11 vs. price of €8.70 (28.2% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the FRA:OM2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orthofix Medical Business Description

Other Exchanges OFIX:USA
Address 3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
60GF Score

Get the complete analysis for FRA:OM2

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price
€12.11
GF Value